Temozolomide in the management of dopamine agonist-resistant prolactinomas

Clinical Endocrinology

Volumn 76, Issue 6, 2012, Pages 877-886

  Whitelaw, B C ^a   Dworakowska, D ^a,e   Thomas, N W ^b   Barazi, S ^b   Riordan Eva, P ^b   King, A P ^b   Hampton, T ^a   Landau, D B ^c   Lipscomb, D ^d   Buchanan, C R ^a   Gilbert, J A ^a   Aylwin, S J B ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Department of Neurosurgery ^*  (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROLACTIN; TEMOZOLOMIDE;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CRANIOTOMY; DECOMPRESSION SURGERY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; NIGHTMARE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RADIATION EXPOSURE; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VISUAL FIELD; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; DACARBAZINE; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROLACTINOMA;

EID: 84860189379     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04373.x     Document Type: Article

References (51)

1. Casanueva, F.F., Molitch, M.E., Schlechte, J.A., et al,. (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology (Oxford), 65, 265-273.
2. Gillam, M.P., Molitch, M.E., Lombardi, G., et al,. (2006) Advances in the treatment of prolactinomas. Endocrine Reviews, 27, 485-534.
3. Klibanski, A., (2010) Clinical practice. Prolactinomas. New England Journal of Medicine, 362, 1219-1226.
4. Losa, M., Mazza, E., Terreni, M.R., et al,. (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. European Journal of Endocrinology, 163, 843-851.
5. Tyrrell, J.B., Lamborn, K.R., Hannegan, L.T., et al,. (1999) Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery, 44, 254-261.
6. Pouratian, N., Sheehan, J., Jagannathan, J., et al,. (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery, 59, 255-266.
7. Kaltsas, G.A., &, Grossman, A.B., (1998) Malignant pituitary tumours. Pituitary, 1, 69-81.
8. Fadul, C.E., Kominsky, A.L., Meyer, L.P., et al,. (2004) Pituitary carcinomas respond to temozolomide. Journal of Neuro-Oncology, 6, 374.
9. Melmed, S., Casanueva, F.F., Hoffman, A.R., et al,. (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96, 273-288.
10. Hegi, M.E., Diserens, A.C., Gorlia, T., et al,. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352, 997-1003.
11. McCormack, A.I., Wass, J.A., &, Grossman, A.B., (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European Journal of Clinical Investigation, 41, 1133-1148.
12. Kovacs, K., Scheithauer, B.W., Lombardero, M., et al,. (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica, 115, 261-262.
13. Widhalm, G., Wolfsberger, S., Preusser, M., et al,. (2009) O-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer, 115, 1070-1080.
14. Mohammed, S., Kovacs, K., Mason, W., et al,. (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery, 64, E773-E774.
15. Moyes, V.J., Alusi, G., Sabin, H.I., et al,. (2009) Treatment of Nelson's syndrome with temozolomide. European Journal of Endocrinology, 160, 115-119.
16. Raverot, G., Sturm, N., de, F.F., et al,. (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. Journal of Clinical Endocrinology and Metabolism, 95, 4592-4599.
17. Bush, Z.M., Longtine, J.A., Cunningham, T., et al,. (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O-methylguanine methyltransferase (MGMT) promoter methylation and expression. Journal of Clinical Endocrinology and Metabolism, 95, E280-E290.
18. Takeshita, A., Inoshita, N., Taguchi, M., et al,. (2009) High incidence of low O-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. European Journal of Endocrinology, 161, 553-559.
19. Bode, H., Seiz, M., Lammert, A., et al,. (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Experimental and Clinical Endocrinology & Diabetes, 118, 760-763.
20. Dillard, T.H., Gultekin, S.H., Delashaw, JB Jr, et al,. (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary, 14, 80-91.
21. Curto, L., Torre, M.L., Ferrau, F., et al,. (2010) Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease-report of a case and literature review. ScientificWorldJournal, 10, 2132-2138.
22. Thearle, M.S., Freda, P.U., Bruce, J.N., et al,. (2011) Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of an aggressive corticotroph pituitary tumor. Pituitary, 14, 418-424.
23. Hagen, C., Schroeder, H.D., Hansen, S., et al,. (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. European Journal of Endocrinology, 161, 631-637.
24. Syro, L.V., Ortiz, L.D., Scheithauer, B.W., et al,. (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 117, 454-462.
25. Syro, L.V., Scheithauer, B.W., Ortiz, L.D., et al,. (2009) Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens), 8, 303-306.
26. Guzel, A., Tatli, M., Senturk, S., et al,. (2008) Pituitary carcinoma presenting with multiple metastases: case report. Journal of Child Neurology, 23, 1467-1471.
27. Fadul, C.E., Kominsky, A.L., Meyer, L.P., et al,. (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. Journal of Neurosurgery, 105, 621-626.
28. McCormack, A.I., McDonald, K.L., Gill, A.J., et al,. (2009) Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clinical Endocrinology (Oxford), 71, 226-233.
29. Morin, E., Berthelet, F., Weisnagel, J., et al,. (2012) Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary, 15, 97-100.
30. Neyns, B., Tosoni, A., Hwu, W.J., et al,. (2010) Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer, 116, 2868-2877.
31. Lau, Q., Scheithauer, B., Kovacs, K., et al,. (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary, 13, 367-379.
32. Ortiga, R.S., Sanchez, V.L.G., Perez, O.M., et al,. (2010) Daily temozolomide therapy in Nelson's syndrome. Endocrine Abstracts, 22, P565.
33. Hart, M.G., Grant, R., Garside, R., et al,. (2008) Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews. CD007415.
34. Stupp, R., Hegi, M.E., Mason, W.P., et al,. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10, 459-466.
35. Su, Y.B., Sohn, S., Krown, S.E., et al,. (2004) Selective CD4 + lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. Journal of Clinical Oncology, 22, 610-616.
36. Kim, S.J., Park, T.S., Lee, S.T., et al,. (2009) Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Annals of Clinical and Laboratory Science, 39, 392-398.
37. Ogura, M., Todo, T., Tanaka, M., et al,. (2011) Temozolomide may induce therapy-related acute lymphoblastic leukaemia. British Journal of Haematology, 154, 663-665.
38. Momota, H.N., Miyakita, Y., &, Shibui, S., (2010) Secondary hematologic malignancies associated with temozolomide (TMZ) in patients with glioma. ASCO Annual Meeting. Chicago. Journal of Clinical Oncology, abstr 2046.
39. Sitbon, S.L., Sanson, M., Prades, M., et al,. (2010) [Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide]. Gynécologie, Obstétrique & Fertilité, 38, 660-662.
40. Tsagarakis, S., Grossman, A., Plowman, P.N., et al,. (1991) Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clinical Endocrinology., 34, 399-406.
41. Minniti, G., Traish, D., Ashley, S., et al,. (2006) Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clinical Endocrinology, 64, 542-548.
42. Sun, D.Q., Cheng, J.J., Frazier, J.L., et al,. (2010) Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurgical Review, 34, 181-189.
43. Snyder, P.J., Fowble, B.F., Schatz, N.J., et al,. (1986) Hypopituitarism following radiation therapy of pituitary adenomas. American Journal of Medicine, 81, 457-462.
44. Minniti, G., Traish, D., Ashley, S., et al,. (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. Journal of Clinical Endocrinology and Metabolism, 90, 800-804.
45. Merchant, T.E., Conklin, H.M., Wu, S., et al,. (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. Journal of Clinical Oncology, 27, 3691-3697.
46. Kovacs, K., Horvath, E., Syro, L.V., et al,. (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Human Pathology, 38, 185-189.
47. Syro, L.V., Uribe, H., Penagos, L.C., et al,. (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clinical Endocrinology (Oxford), 65, 552-553.
48. Murakami, M., Mizutani, A., Asano, S., et al,. (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery, 68, E1761-E1767.
49. Lim, S., Shahinian, H., Maya, M.M., et al,. (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncology, 7, 518-520.
50. Byrne, S., Karapetis, C., &, Vrodos, N., (2009) A novel use of temozolomide in a patient with malignant prolactinoma. Journal of Clinical Neuroscience, 16, 1694-1696.
51. Neff, L.M., Weil, M., Cole, A., et al,. (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary, 10, 81-86.